Clinical trial · Interventional
A Pilot Study of the Effect of High Protein Supplement and Exercise Therapy on Preservation of Skeletal Muscle Mass and Quality of Life in Patients With Gastric Cancer and Pancreatic Cancer Treated With Chemotherapy
NCT05573776CI-TRIAL-00076858completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
For gastric and pancreatic cancer patients scheduled for primary chemotherapy, we would like to report muscle mass preservation and improvement in quality of life in Chinese characters that received only exercise therapy and high protein supplements at the same time
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Exercise Therapy, High Protein supplement | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Exercise Therapy, High Protein supplement
- interventionNames
- Other: Exercise Therapy, High Protein supplement
Primary outcomes (2)
- measure
- Comparison of muscle mass between exercise therapy alone and high protein supplement combination groups
- timeFrame
- 6weeks
- description
- Comparison of muscle mass between the exercise therapy single group and the high-protein supplement combination group as assessed by Bioelectrical impedance analsis (BIA) (performed in Week 6)
- measure
- Comparison of muscle variation between exercise therapy alone and high protein supplement combination groups
- timeFrame
- 6weeks
- description
- Comparison of muscle variation between the exercise therapy single group and the high-protein supplement combination group as assessed by Bioelectrical impedance analsis (BIA) (performed in Week 6)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: 1. Has provided signed written informed Consent 2. Has a histologically confirmed gastric or pancreatic cancer 3. Has a patient scheduled for chemotherapy - Patients who are scheduled to be treated with TS-1 or Xelox for gastric cancer-adjuvant chemotherapy - Patients scheduled for primary chemotherapy for pancreatic cancer-progressive/transitional diseases Exclusion Criteria: 1. Age under 19 or over 90 year of age 2. Eastern Cooperative Oncology Group (ECOG) ≥ 2 3. Patients with severe malnutritional evaluation (PG-SGAC) 4. Any of the following within 3 months prior to study recruitment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, NYHA class III or IV congestive heart failure, stroke or transient ischemic attack. 5. A person with previous uncontrolled seizures, central nervous system or psychological disorders 6. Have uncontrolled active infection or sepsis 7. Have deep vein thrombosis occurs within 4 weeks prior to the start of test recruitment 8. Severe acute or chronic conditions that may reduce the patient's ability to participate in clinical trials or make it difficult to interpret clinical trial results 9. Pregnant or lactating women. Pregnancy test results are positive in childbearing women 10. Gastrointestinal obstruction, malabsorption syndrome, or diseases that significantly affect digestive functions
References
Publications (0)
Data not yet available
No reference posted for this study.